Enanta Pharmaceuticals (ENTA) vs Ocugen (OCGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Enanta Pharmaceuticals (ENTA) has outperformed Ocugen (OCGN) over the past year, gaining 11.6% versus a loss of 43.2%. Over five years, ENTA leads with a -82.7% price change compared with -88.5% for OCGN. Enanta Pharmaceuticals is the larger company by market cap ($360.3 million vs $339.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENTA | OCGN |
|---|---|---|
| Share price | $12.37 | $1.00 |
| Market cap | $360.28M | $339.11M |
| 1-day change | +1.64% | -3.85% |
| YTD return | -21.56% | -25.93% |
| 1-year return | +11.64% | -43.18% |
| 5-year return | -82.69% | -88.45% |
| EPS (TTM) | $-2.47 | $-0.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.15 | $2.73 |
| 52-week low | $10.20 | $0.97 |
| Distance from 52-week high | -27.87% | -63.30% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +76.48% | +1117.00% |
| Average volume | 227.13K | 5.82M |
| Shares outstanding | 29.13M | 339.11M |
| Employees | 120 | 116 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ENTA has outperformed OCGN by 54.8 percentage points over the past year.
About Enanta Pharmaceuticals
ENTA stock →Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis.
Healthcare · Biotechnology · 120 employees
About Ocugen
OCGN stock →Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.
Healthcare · Biotechnology · 116 employees
ENTA vs OCGN FAQ
Which is bigger, Enanta Pharmaceuticals or Ocugen?
Enanta Pharmaceuticals (ENTA) is larger, with a market capitalization of $360.28M compared with $339.11M for Ocugen (OCGN).
Which stock has performed better over the past year, ENTA or OCGN?
ENTA returned +11.64% over the past 12 months, compared with -43.18% for OCGN (price return, excluding dividends). Past performance does not predict future results.
Are Enanta Pharmaceuticals and Ocugen in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.